Suppr超能文献

激活性杀伤细胞免疫球蛋白样受体(KIR)基因的数量与肾移植受者中巨细胞病毒(CMV)感染/再激活的发生率呈负相关。

The number of activating KIR genes inversely correlates with the rate of CMV infection/reactivation in kidney transplant recipients.

作者信息

Stern M, Elsässer H, Hönger G, Steiger J, Schaub S, Hess C

机构信息

Clinic for Hematology, Department of Research, University Hospital Basel, Switzerland.

出版信息

Am J Transplant. 2008 Jun;8(6):1312-7. doi: 10.1111/j.1600-6143.2008.02242.x. Epub 2008 Apr 29.

Abstract

Viral infection is a common complication after kidney transplantation. The role of natural killer cells (NK cells) in this setting remains unknown. NK cells express activating and inhibitory killer cell immunoglobulin-like receptors (KIR). We analyzed whether activating KIR genes carried by kidney transplant-recipients influence the rate of viral infection during the first year after transplantation. In patients with a KIR A/A genotype (n = 40, KIR2DS4 only activating KIR) the rate of cytomegalovirus (CMV) infection and reactivation was 36%, as compared to 20% in transplant recipients with more than one activating KIR gene (KIR B/X genotype, n = 82, p = 0.04). Adjusting for other risk factors in Cox regression, the relative risk of B versus A genotype patients was 0.34 (95% CI 0.15-0.76, p = 0.009). The degree of protection increased with the number of activating KIR genes. Symptomatic CMV disease was only observed in four individuals, all carrying a KIR A/A genotype. As for viral infections other than CMV, and for bacterial infections, no KIR-linked protective effect could be detected. Also, graft function and the rate-rejection episodes were similar in KIR A/A and KIR B/X genotype individuals. This study supports a role for activating KIR in the control of CMV infection after kidney transplantation.

摘要

病毒感染是肾移植术后常见的并发症。自然杀伤细胞(NK细胞)在此情况下的作用尚不清楚。NK细胞表达激活型和抑制型杀伤细胞免疫球蛋白样受体(KIR)。我们分析了肾移植受者携带的激活型KIR基因是否会影响移植后第一年的病毒感染率。在KIR A/A基因型患者中(n = 40,仅KIR2DS4为激活型KIR),巨细胞病毒(CMV)感染和再激活率为36%,而携带一个以上激活型KIR基因的移植受者(KIR B/X基因型,n = 82)的这一比率为20%(p = 0.04)。在Cox回归中对其他风险因素进行校正后,B基因型患者与A基因型患者相比的相对风险为0.34(95%可信区间0.15 - 0.76,p = 0.009)。保护程度随激活型KIR基因数量的增加而提高。仅在4名个体中观察到有症状的CMV疾病,所有这些个体均携带KIR A/A基因型。至于除CMV以外的病毒感染以及细菌感染,未检测到与KIR相关的保护作用。此外,KIR A/A和KIR B/X基因型个体的移植肾功能和排斥反应发生率相似。本研究支持激活型KIR在肾移植后控制CMV感染中发挥作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验